If you know, you know.
A medicines company that can't develop a new molecule and doesn't need to. The medicines already exist. The prices are the problem. We know exactly how they were set, because so do you.
Invest in bringing cheaper medicines to the NHS.
Founders' round, 2027. Invitation only. Capital at risk.
One company notices a strength the NHS needs and nobody makes. It licenses it. It is the only supplier, so the Tariff pays whatever the list price says, until a second supplier turns up. Often nobody does.
So the NHS pays thirty, forty, fifty times what the tablet costs to make, and pharmacists split bigger tablets with a knife to avoid it. Everyone in that room knew. You may have been one of them. We were.
We launch at a price the NHS can defend, and we cut it when a second supplier would have forced us to, whether or not one turns up. If we ever hold a price because we can, you will see it in the four numbers. And you will own the company, so you can stop us.
Regulatory. Quality. Safety. Field. Made redundant from the brands they built, or still there and tired. Members, not customers. Owners, not staff. If you have sat in the meeting where the price was set, you are qualified. If you are in medicines optimisation trying to manage the consequences, you are qualified too.
Proven medicines, in the strengths the NHS needs and nobody makes, at a price we publish before the NHS asks. First product in registration 2027. The members choose the rest.
If you want to invest in bringing cheaper medicines to the NHS, rather than just talk about it, ask for an invitation.
This room is for the founders' circle. If you have an invitation, it came with a word. If you don't, you know who to ask.
This is the first room. It gets bigger as the circle does. When it opens for real it will carry the four numbers for every product, the board minutes, the pipeline vote and the quarterly letter, unedited.
Counted by hand, updated weekly.
Nine pages on what Fair Dose is and how it works. No terms, no numbers on the round. Those come through an approved platform in 2027, to members, with the risk warnings they deserve.